Ignite Creation Date:
2025-12-24 @ 2:16 PM
Ignite Modification Date:
2026-01-06 @ 7:20 AM
Study NCT ID:
NCT05194995
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-04
First Post:
2021-12-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Sponsor:
Allist Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-17
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-27
First Submit QC Date:
None
Study First Post Date:
2022-01-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-03
Last Update Post Date:
2025-04-04
Last Update Post Date Type:
ACTUAL